Clinical Trial: Ezetimibe for Patients With Chronic Hepatitis D

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Ezetimibe for Patients With Chronic Hepatitis D

Brief Summary: Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection

Detailed Summary:
Sponsor: Ziauddin Hospital

Current Primary Outcome: • Decline of HDV RNA quantitative measurements of >1 logs from baseline [ Time Frame: 12 weeks of therapy ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Ziauddin Hospital

Dates:
Date Received: March 28, 2017
Date Started: January 2017
Date Completion: October 2017
Last Updated: March 28, 2017
Last Verified: March 2017